Lack of association between clinical and cognitive change in first-episode psychosis: The first 6 weeks of treatment

Canadian Journal of Psychiatry

Volumn 53, Issue 12, 2008, Pages 839-847

  González Blanch, César ^a   Crespo Facorro, Benedicto ^a   Álvarez Jiménez, Mario ^a   Rodríguez Sánchez, José Manuel ^a   Pérez Iglesias, Rocío ^a   Pelayo Terán, José María ^a   Martínez García, Obdulia ^a   Vázquez Barquero, José Luis ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Antipsychotic treatments; Clinical dimensions; Cognitive functioning; First episode psychosis; Schizophrenia

Indexed keywords

BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DECLARATIVE MEMORY; FEMALE; FOLLOW UP; HUMAN; MALE; NEUROLOGIC EXAMINATION; PSYCHOSIS; VISUOMOTOR COORDINATION; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION DISORDERS; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 58149234089     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Malla A, Payne J. First-episode psychosis: psychopathology, quality of life, and functional outcome. Schizophr Bull. 2005;31(3):650-671.
2. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand. 2007;115(2):93-100.
3. Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, et al. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry. 2006;67(10):1511-1521.
4. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473-479.
5. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26(1):119-136.
6. Hyman SE, Fenton WS. Medicine. What are the right targets for psychopharmacology? Science. 2003;299(5605):350 -351.
7. Gold JM. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res. 2004;72(1):21-28.
8. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31(1):5-19.
9. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157(4):549-559.
10. Heydebrand G, Weiser M, Rabinowitz J, et al. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68(1):1-9.
11. Mohamed S, Paulsen JS, O'Leary D, et al. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry. 1999;56(8):749-754.
12. Fitzgerald D, Lucas S, Redoblado MA, et al. Cognitive functioning in young people with first episode psychosis: relationship to diagnosis and clinical characteristics. Aust N Z J Psychiatry. 2004;38(7):501-510.
13. Daban C, Amado I, Bourdel MC, et al. Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia. J Psychiatr Res. 2005;39(4):391-398.
14. Lucas S, Fitzgerald D, Redoblado-Hodge MA, et al. Neuropsychological correlates of symptom profiles in first episode schizophrenia. Schizophr Res. 2004;71(2-3):323-330.
15. Gold S, Arndt S, Nopoulos P, et al. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry. 1999;156(9):1342-1348.
16. Censits DM, Ragland JD, Gur RC, et al. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr Res. 1997;24(3):289-298.
17. Hoff AL, Riordan H, O'Donnell DW, et al. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry. 1992;149(7):898-903.
18. Schuepbach D, Keshavan MS, Kmiec JA, et al. Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia. Schizophr Res. 2002;53(3):249-261.
19. Rund BR, Melle I, Friis S, et al. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry. 2004;161(3):466-472.
20. González-Blanch C, Alvarez-Jimenez M, Rodriguez-Sanchez JM, et al. Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns. Eur Arch Psychiatry Clin Neurosci. 2006;256(6):364-371.
21. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders. New York (NY): Biometrics Research Department, New York State Psychiatric Institute; 1995.
22. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992;49(8):615-623.
23. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City (IA): University of Iowa; 1983.
24. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City (IA): University of Iowa; 1981.
25. Grube BS, Bilder RM, Goldman RS. Meta-analysis of symptom factors in schizophrenia. Schizophr Res. 1998;31(2-3):113-120.
26. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57(1):289-300.
27. Harvey PD, Green MF, Bowie C, et al. The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. Psychopharmacology (Berl). 2006;187(3):356-363.
28. Hong KS, Kim JG, Koh HJ, et al. Effects of risperidone on information processing and attention in first-episode schizophrenia. Schizophr Res. 2002;53(1-2):7-16.
29. Bell MD, Mishara AL. Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments. Schizophr Res. 2006;81(1):17-27.
30. Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand. 1997;95(1):40-43.
31. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57(3):249-258.
32. Kern RS, Green MF, Marshall BD Jr, et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull. 1999;25(2):223-232.
33. Purdon SE, Labelle A, Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr Res. 2001;48(1):57-67.
34. Green MF, Marshall BD Jr, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry. 1997;154(6):799-804.
35. Reilly JL, Harris MS, Keshavan MS, et al. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry. 2006;63(11):1189-1197.
36. Reilly JL, Harris MS, Khine TT, et al. Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biol Psychiatry. 2007;62(7):818-821.
37. Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25(2):201-222.
38. Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8(3):457-472.
39. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158(2):176-184.
40. González-Blanch C, Crespo-Facorro B, Alvarez-Jiménez M, et al. Pretreatment predictors of cognitive deficits in early psychosis. Psychol Med. 2008;38(5):737-746.
41. González-Blanch C, Crespo-Facorro B, Alvarez-Jiménez M, et al. Cognitive dimensions in first-episode schizophrenia spectrum disorders. J Psychiatr Res. 2007;41(11):968-977.
42. Wesnes K, Pincock C. Practice effects on cognitive tasks: a major problem? Lancet Neurol. 2002;1(8):473.
43. Duff K, Beglinger LJ, Schultz SK, et al. Practice effects in the prediction of long-term cognitive outcome in three patient samples: a novel prognostic index. Arch Clin Neuropsychol. 2007;22(1):15-24.
44. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64(10):1115-1122.
45. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002;190(9):583-592.
46. Perlis RH, Perlis CS, Wu Y, et al. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry. 2005;162(10):1957-1960.
47. Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004;161(1):116-124.
48. Nishiyama K, Sugishita M, Kurisaki H, et al. Reversible memory disturbance and intelligence impairment induced by long-term anticholinergic therapy. Intern Med. 1998;37(6):514-518.
49. Wykes T, Reeder C, Landau S, et al. Cognitive remediation therapy in schizophrenia: randomised controlled trial. Br J Psychiatry. 2007;190:421-427.
50. Wykes T, Reeder C, Williams C, et al. Are the effects of cognitive remediation therapy (CRT) durable? Results from an exploratory trial in schizophrenia. Schizophr Res. 2003;61(2-3):163-174.